S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:LMAT

LeMaitre Vascular Competitors

$51.39
+4.94 (+10.64 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.12
Now: $51.39
$54.96
50-Day Range
$41.60
MA: $46.50
$49.20
52-Week Range
$18.76
Now: $51.39
$54.96
Volume308,612 shs
Average Volume116,708 shs
Market Capitalization$1.05 billion
P/E Ratio55.26
Dividend Yield0.82%
Beta1.43

Competitors

LeMaitre Vascular (NASDAQ:LMAT) Vs. SWAV, CMD, MMSI, NUVA, ATRC, and INO

Should you be buying LMAT stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to LeMaitre Vascular, including ShockWave Medical (SWAV), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), AtriCure (ATRC), and Inovio Pharmaceuticals (INO).

LeMaitre Vascular (NASDAQ:LMAT) and ShockWave Medical (NASDAQ:SWAV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares LeMaitre Vascular and ShockWave Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40
ShockWave Medical$42.93 million93.18$-51,110,000.00($2.14)-54.56

LeMaitre Vascular has higher revenue and earnings than ShockWave Medical. ShockWave Medical is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for LeMaitre Vascular and ShockWave Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LeMaitre Vascular04302.43
ShockWave Medical04202.33

LeMaitre Vascular presently has a consensus target price of $36.1667, suggesting a potential downside of 29.62%. ShockWave Medical has a consensus target price of $109.50, suggesting a potential downside of 6.22%. Given ShockWave Medical's higher probable upside, analysts clearly believe ShockWave Medical is more favorable than LeMaitre Vascular.

Risk and Volatility

LeMaitre Vascular has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, ShockWave Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Insider and Institutional Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 88.8% of ShockWave Medical shares are owned by institutional investors. 16.5% of LeMaitre Vascular shares are owned by insiders. Comparatively, 15.3% of ShockWave Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares LeMaitre Vascular and ShockWave Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LeMaitre Vascular15.41%12.32%8.45%
ShockWave Medical-108.73%-30.28%-25.31%

Summary

LeMaitre Vascular beats ShockWave Medical on 11 of the 14 factors compared between the two stocks.

Cantel Medical (NYSE:CMD) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Cantel Medical and LeMaitre Vascular, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cantel Medical12102.00
LeMaitre Vascular04302.43

Cantel Medical presently has a consensus price target of $71.50, suggesting a potential downside of 3.74%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Cantel Medical's higher possible upside, equities research analysts plainly believe Cantel Medical is more favorable than LeMaitre Vascular.

Volatility & Risk

Cantel Medical has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Cantel Medical and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cantel Medical3.38%11.19%4.10%
LeMaitre Vascular15.41%12.32%8.45%

Earnings & Valuation

This table compares Cantel Medical and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cantel Medical$1.02 billion3.09$13.71 million$1.6545.02
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40

LeMaitre Vascular has lower revenue, but higher earnings than Cantel Medical. Cantel Medical is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 10.7% of Cantel Medical shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LeMaitre Vascular beats Cantel Medical on 8 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Merit Medical Systems and LeMaitre Vascular, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
LeMaitre Vascular04302.43

Merit Medical Systems presently has a consensus price target of $64.3750, suggesting a potential upside of 15.53%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, equities research analysts plainly believe Merit Medical Systems is more favorable than LeMaitre Vascular.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Merit Medical Systems and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
LeMaitre Vascular15.41%12.32%8.45%

Earnings & Valuation

This table compares Merit Medical Systems and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.11$5.45 million$1.4638.16
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40

LeMaitre Vascular has lower revenue, but higher earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LeMaitre Vascular beats Merit Medical Systems on 8 of the 14 factors compared between the two stocks.

NuVasive (NASDAQ:NUVA) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

84.2% of LeMaitre Vascular shares are owned by institutional investors. 0.9% of NuVasive shares are owned by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for NuVasive and LeMaitre Vascular, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NuVasive27702.31
LeMaitre Vascular04302.43

NuVasive presently has a consensus price target of $60.4667, suggesting a potential upside of 0.23%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given NuVasive's higher possible upside, equities research analysts plainly believe NuVasive is more favorable than LeMaitre Vascular.

Volatility & Risk

NuVasive has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares NuVasive and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NuVasive-0.84%8.00%3.06%
LeMaitre Vascular15.41%12.32%8.45%

Earnings & Valuation

This table compares NuVasive and LeMaitre Vascular's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuVasive$1.17 billion2.65$65.23 million$2.4724.43
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40

NuVasive has higher revenue and earnings than LeMaitre Vascular. NuVasive is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats NuVasive on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

94.7% of AtriCure shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 5.8% of AtriCure shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for AtriCure and LeMaitre Vascular, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure00703.00
LeMaitre Vascular04302.43

AtriCure currently has a consensus price target of $66.00, suggesting a potential upside of 1.12%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given AtriCure's stronger consensus rating and higher possible upside, research analysts clearly believe AtriCure is more favorable than LeMaitre Vascular.

Risk and Volatility

AtriCure has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares AtriCure and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-21.74%-14.83%-7.77%
LeMaitre Vascular15.41%12.32%8.45%

Valuation & Earnings

This table compares AtriCure and LeMaitre Vascular's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million12.73$-35,190,000.00($1.07)-61.00
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40

LeMaitre Vascular has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats AtriCure on 8 of the 14 factors compared between the two stocks.

Inovio Pharmaceuticals (NASDAQ:INO) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 84.2% of LeMaitre Vascular shares are held by institutional investors. 4.0% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 16.5% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Inovio Pharmaceuticals and LeMaitre Vascular, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals15302.22
LeMaitre Vascular04302.43

Inovio Pharmaceuticals currently has a consensus price target of $15.3333, suggesting a potential upside of 38.14%. LeMaitre Vascular has a consensus price target of $36.1667, suggesting a potential downside of 29.62%. Given Inovio Pharmaceuticals' higher possible upside, research analysts clearly believe Inovio Pharmaceuticals is more favorable than LeMaitre Vascular.

Risk and Volatility

Inovio Pharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Profitability

This table compares Inovio Pharmaceuticals and LeMaitre Vascular's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
LeMaitre Vascular15.41%12.32%8.45%

Valuation & Earnings

This table compares Inovio Pharmaceuticals and LeMaitre Vascular's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million504.63$-119,360,000.00($1.16)-9.57
LeMaitre Vascular$117.23 million8.92$17.93 million$0.8858.40

LeMaitre Vascular has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Summary

LeMaitre Vascular beats Inovio Pharmaceuticals on 11 of the 13 factors compared between the two stocks.


LeMaitre Vascular Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SWAV
ShockWave Medical
1.4$116.76+0.2%$4.00 billion$42.93 million-57.80Analyst Report
Insider Selling
News Coverage
Cantel Medical logo
CMD
Cantel Medical
1.3$74.28+1.2%$3.14 billion$1.02 billion88.43News Coverage
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$55.72+1.6%$3.10 billion$994.85 million-105.13Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
NuVasive logo
NUVA
NuVasive
1.3$60.33+3.0%$3.09 billion$1.17 billion-274.23Earnings Announcement
AtriCure logo
ATRC
AtriCure
1.5$65.27+0.8%$2.94 billion$230.81 million-56.76Earnings Announcement
Analyst Report
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$11.10+3.5%$2.07 billion$4.11 million-8.16Upcoming Earnings
LUNG
Pulmonx
0.7$56.83+5.0%$2.03 billion$32.60 million0.00Upcoming Earnings
High Trading Volume
News Coverage
AXNX
Axonics Modulation Technologies
1.5$50.31+1.0%$2.00 billion$13.82 million-25.67Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
SILK
Silk Road Medical
1.1$54.77+0.3%$1.86 billion$63.35 million-44.89Upcoming Earnings
Insider Selling
News Coverage
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$41.30+0.2%$1.66 billion$236.54 million-62.57
Luminex logo
LMNX
Luminex
1.8$32.52+1.4%$1.51 billion$334.64 million83.39
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.4$19.55+3.8%$1.40 billion$88.02 million-47.68Earnings Announcement
Gap Up
Alphatec logo
ATEC
Alphatec
0.8$16.05+1.4%$1.26 billion$113.43 million-14.59Upcoming Earnings
Atrion logo
ATRI
Atrion
1.1$624.90+2.4%$1.16 billion$155.07 million35.21
MDXG
MiMedx Group
0.0$9.91+1.6%$1.10 billion$299.26 million-10.54News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.3$54.46+0.3%$1.06 billion$72.55 million-37.82Upcoming Earnings
Analyst Downgrade
Cerus logo
CERS
Cerus
1.5$6.14+5.0%$1.03 billion$74.65 million-15.74Earnings Announcement
News Coverage
Gap Up
SIBN
SI-BONE
1.2$31.39+0.9%$1.02 billion$67.30 million-19.62
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.4$50.82+1.5%$991.40 million$189.49 million-112.93Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
CryoLife logo
CRY
CryoLife
1.8$25.25+0.0%$981.14 million$276.22 million-66.45
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$46.51+0.2%$899.22 million$459.95 million38.76
AngioDynamics logo
ANGO
AngioDynamics
1.4$20.95+2.4%$795.35 million$264.16 million-4.69
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.60+0.8%$760.37 million$154.60 million-46.09Upcoming Earnings
Intersect ENT logo
XENT
Intersect ENT
1.2$22.81+1.5%$746.32 million$109.14 million-11.94
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$29.25+0.9%$741.25 millionN/A-12.89Earnings Announcement
Surmodics logo
SRDX
Surmodics
1.5$52.15+0.9%$717.38 million$94.86 million651.88Unusual Options Activity
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.25+5.2%$708.36 million$123.86 million70.85Upcoming Earnings
VAPO
Vapotherm
1.5$24.30+4.7%$623.56 million$48.10 million-11.57Analyst Report
AFIB
Acutus Medical
1.5$20.76+0.7%$578.08 million$2.84 million0.00Upcoming Earnings
SeaSpine logo
SPNE
SeaSpine
1.3$18.92+3.0%$522.82 million$159.08 million-11.33Upcoming Earnings
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$36.70+1.9%$521.69 million$114.51 million-78.09Upcoming Earnings
News Coverage
RCEL
AVITA Medical
1.4$21.74+7.1%$470.21 million$14.26 million-10.50News Coverage
Accuray logo
ARAY
Accuray
2.3$4.98+3.6%$462.63 million$382.93 million35.57
CLPT
ClearPoint Neuro
1.2$23.42+7.6%$455.87 million$11.22 million-53.23Upcoming Earnings
Analyst Revision
Gap Down
PROF
Profound Medical
1.5$22.03+2.1%$445.20 million$4.17 million-18.83Upcoming Earnings
ICAD
iCAD
1.5$18.49+7.0%$425.14 million$31.34 million-19.46Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.42+3.1%$406.72 million$24.95 million-28.55Upcoming Earnings
Co-Diagnostics logo
CODX
Co-Diagnostics
1.7$13.76+11.9%$388.98 million$220,000.0016.99
UFP Technologies logo
UFPT
UFP Technologies
1.4$49.52+1.8%$371.15 million$198.38 million24.76Upcoming Earnings
APYX
Apyx Medical
1.0$10.45+0.6%$358.17 million$28.15 million-22.23
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$2.29+1.7%$338.82 million$8.34 million-3.32Upcoming Earnings
Gap Up
Utah Medical Products logo
UTMD
Utah Medical Products
1.0$84.40+0.4%$307.22 million$46.90 million26.62
PAVmed logo
PAVM
PAVmed
1.2$4.20+6.4%$302.00 millionN/A-5.53Earnings Announcement
Neuronetics logo
STIM
Neuronetics
1.5$15.53+1.1%$294.68 million$62.66 million-9.24Upcoming Earnings
SOLY
Soliton
1.2$13.28+2.7%$281.40 millionN/A-17.71Upcoming Earnings
IRadimed logo
IRMD
IRadimed
1.7$22.30+1.8%$273.62 million$38.52 million69.69Analyst Downgrade
TELA
TELA Bio
2.1$15.37+6.4%$221.82 million$15.45 million-5.28Insider Buying
DarioHealth logo
DRIO
DarioHealth
0.9$26.60+1.4%$215.83 million$7.56 million-3.33Analyst Report
Titan Medical logo
TMDI
Titan Medical
0.7$2.16+1.4%$195.71 millionN/A216.00
LYRA
Lyra Therapeutics
1.6$14.92+6.2%$192.87 millionN/A0.00Upcoming Earnings
News Coverage
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.